Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYPluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18PREV STORYAvenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights